Best Undervalued Stocks To Watch For 2018

Value investing may not be dead after all. After a lousy 2015, in which mutual funds that focus on cheap U.S. stocks of all sizes shed an average of 4.7%, bargain hunters have rebounded impressively. Over the past year, the average value fund earned 10.9%.

See Also: 6 Value Stock Picks in a Pricey Market

Few funds have benefited more from the shift in investor sentiment than TCW Relative Value Mid Cap (TGVNX). TCW lost 12.2% in 2015, trailing the typical fund that focuses on undervalued midsize firms by 6.8 percentage points. But over the past year, it outpaced its typical peer by 5.9 percentage points.

Whether markets are friendly or not, manager Diane Jaffee sticks with her strategy. She starts with stocks with market values of $1 billion to $31 billion. She and her team compare five measures of valuedividend yield and the ratio of price to earnings, sales, cash flow and book value (assets minus liabilities)for each stock with comparable figures for the Russell Midcap index.

Best Undervalued Stocks To Watch For 2018: KLA-Tencor Corporation(KLAC)

Advisors’ Opinion:

  • [By JPMorga]

    KLA-Tencor, which is in the process of being acquired by Lam Research, continues to deliver best-in-class dividends as a result of its solid operational performance and strong free cash flow generation. The company’s current dividend yield is at 3.1%. 

  • [By Laurie Kulikowski]

    We rate KLA-TENCOR CORP as a Hold with a ratings score of C. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company’s strengths can be seen in multiple areas, such as its increase in net income, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. 

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that KLAC’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

     

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income increased by 45.2% when compared to the same quarter one year prior, rising from $72.23 million to $104.90 million.

     

  • [By Jim Cramer]

    The company’s current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Semiconductors & Semiconductor Equipment industry and the overall market, KLA-TENCOR CORP’s return on equity significantly exceeds that of both the industry average and the S&P 500.

     

  • [By Jim Cramer]

    The debt-to-equity ratio is very high at 10.70 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company’s weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.00, which shows the ability to cover short-term cash needs.

     

Best Undervalued Stocks To Watch For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $98.63 on Wednesday, down about 5.7% compared with Tuesday’s closing price of $04.64. The stock’s 52-week high is $157.02. Volume totaled about 8.5 million shares, around 4 times the daily average of about 3 million. The company announced several executive changes on Tuesday and the fallout has continued.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) sunk to the bottom of the S&P 500 today, a drop that is being attributed to revelations on Wednesday night that it had to delay its 10-Q because of a whistle blower investigation into its sales practices.

    Getty Images

    Shares of Alexion Pharmaceuticals tumbled 10% to $$113.62 today, while the S&P 500 dipped 0.1% to 2,164.45.

    After speaking with Alexion CEO Vika Sinha, Citigroup’s Robyn Karnauskas and Mohit Bansal see a buying opportunity. “As we highlighted in our previous note, we cannot envision anything that changes numbers fundamentally and see this weakness as buying opportunity,” they write. They also write that they looked at the companies past financials and saw no red flags, while noting that Soliris, the drug that is causing all the problems, “is sold on named patient basis, therefore, chances of fake sales are very minimal.”

    Alexion Pharmaceuticals market capitalization fell to $25.4 billion today from $28.5 billion yesterday.

Best Undervalued Stocks To Watch For 2018: Covanta Holding Corporation(CVA)

Advisors’ Opinion:

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Both of these stocks are overlooked, undervalued, and cash flow machines. The companies are Ascent Capital Group (ASCMA) and Covanta Holdings (CVA).

Leave a Reply

Your email address will not be published. Required fields are marked *